Loading stock data…
Prothena Corporation plc (PRTA)
$9.97-0.05 (-0.50%)
After Hours$9.97+0.00 (+0.00%)· Last close Jun 29
Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Prothena Corporation plc in the Healthcare sector is trading at $9.97 with a market capitalization of $411M. Wall Street consensus targets $21.40 (5 analysts), implying a +114.6% move over the next 12 months. The stock is currently 16% below its 52-week high of $11.80, remaining 3.1% above its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +114.6% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $51.08M↑ | $21,000↓ | $2.42M↓ | $4.42M↑ | $2.83M |
| Gross Profit | — | — | — | — | — |
| Operating Income | $25.79M↑ | -$27.21M↑ | -$39.76M↑ | -$52.01M↑ | -$65.58M |
| Net Income | $32.72M↑ | -$21.59M↑ | -$36.54M↑ | -$125.77M↓ | -$60.20M |
Peer Comparison
JNJUNHPFE
Fundamentals
Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation. Its product pipeline includes Prasinezumab, an investigational humanized...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$411.50M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-48.36%
Volume
Today's trading volume
407,042
Recent News
Adaptive Biotechnologies (ADPT) Moves 9.7% Higher: Will This Strength Last?
Adaptive Biotechnologies (ADPT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
High Insider Ownership Growth Stocks To Watch In May 2026
Over the last 7 days, the United States market has risen by 1.3%, contributing to a robust 28% increase over the past year, with earnings expected to grow by 17% annually. In this thriving environment, growth companies with high insider ownership can be particularly appealing as they often signal confidence from those closest to the business and may align well with current market optimism.
Earnings Beat: Prothena Corporation plc Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
Prothena Corporation plc ( NASDAQ:PRTA ) last week reported its latest quarterly results, which makes it a good time...
Stock Market Today, April 29: KalVista Pharmaceuticals Surges on Chiesi Group Acquisition Announcement
On April 29, 2026, a rare-disease deal reshapes biotech M&A expectations as investors weigh tender terms.
3 Growth Companies Insiders Are Eager To Hold
In the last week, the United States market has stayed flat, but over the past 12 months, it has risen by an impressive 29%, with earnings forecasted to grow by 16% annually. In this environment of growth and stability, companies with high insider ownership can be particularly appealing as they often signal strong confidence from those closest to the business's operations and future prospects.